Aveanna Healthcare Holdings, Inc. (AVAH) stock intrinsic value fair value estimate & owner earnings analysis

Aveanna Healthcare, based in Atlanta, provides home-based care from locations in 38 states, with concentrations in Texas, Pennsylvania and California. Private Duty Services (82% of fiscal 2025 revenue of $2.43 billion) is mostly skilled private duty nursing for children with medical complexity, who are referred largely by children's hospitals and often stay into adulthood (about 30% of these patients are over 18). Home Health & Hospice made up 10% of revenue and Medical Solutions 8%. The main payers are state Medicaid programs and Medicaid managed-care plans. A 1967 federal mandate, the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit, requires states to cover medically necessary care for children under 21, and it explicitly covers private duty nursing and pediatric therapy. That mandate is the foundation of the business. The swing factor is the gap between what states pay and what the company must pay its nurses, most of whom are licensed practical nurses in a tight labor market. Earnings history. We measure the cash the business produces for its owners: operating cash flow with timing swings in working capital removed, minus stock compensation and the capital spending needed to maintain the business. That capital spending is small, about $5 million a year. Non-cash items are added back, including about $974 million of goodwill write-downs from 2020 to 2023 and a $143 million non-cash tax benefit in 2025. After interest, owner earnings per share were $0.20 in 2020, $0.09 in 2021, -$0.29 in 2022, $0.06 in 2023, $0.10 in 2024 and $0.60 in 2025. Because the company carries heavy floating-rate debt, we value the business before its lenders and then subtract what it owes. On that basis the business generated about $116 million in 2023 and $136 million in 2024. In 2025 it generated about $265 million, before $16.0 million of one-time refinancing fees and excluding about $23 million of receipts from interest-rate hedges that have now expired or are about to. The jump came from state Medicaid and managed-care rate increases (the private duty revenue rate rose 11.4%), higher volume (up 11.0%) and the June 2025 purchase of Thrive Skilled Pediatric Care. Part of the rate gain came from collecting old receivables that had been fully written off, which will not repeat, and fiscal 2025 had 53 weeks. We therefore set the normal level at about $240 million a year, or $1.07 per current diluted share. That is a little below fiscal 2025 on a per-share basis, so no acceleration is assumed. Business cash flow per share rose about 65% in 2025. The second half of 2025 and the first half of 2026 each ran at or above the $240 million pace, which supports the level. However, operating income in the second quarter of 2026 ($80.0 million) was flat against the same quarter of 2025 ($80.0 million). That is despite the Thrive purchase and about $169 million spent on acquisitions in the first half of 2026, which argues against building in growth. Debt. At January 3, 2026 the company owed $1,487 million. This was $1,322 million of term loans due September 2032 at SOFR plus 3.75% (7.47%), plus $165 million under a receivables facility that runs to about mid-2028. Against that it held $193 million of cash. We treat $143 million as surplus and add about $107 million for paying roughly 7.5% instead of 6% for the roughly six years to 2032. Its hedges ($520 million of swaps at 2.03%, which ended June 30, 2026, and $880 million of caps at 2.96%, which end February 28, 2027) were worth only about $9 million at year-end. Net debt is therefore about $1.44 billion. The company spent about $169 million on acquisitions in the first half of 2026, consistent with the $175.5 million cash purchase of Family First Homecare (27 locations in seven states) announced March 12, 2026. The base case treats that spending as worth what was paid, so neither the cash nor the acquired earnings are counted. Base case ($6.27 per share). Business cash flow holds flat at about $240 million for ten years. The 2025 rate increases are assumed to stay in state fee schedules, but no further rate gains, share gains or acquisition-driven growth are credited. Acquisitions do not count as proven growth because they have been lumpy rather than a steady routine: about $667 million in 2021, almost nothing in 2023-2024, then Thrive, paid partly in stock, and Family First. For the following 15 years the EPSDT mandate keeps demand in place, but cash flow is set lower at $200 million. This reflects how thin results were in 2022-2024, years in which the filings describe caregiver shortages and inflationary wage pressure. Nothing in the filings supports reimbursement terms beyond that, so the case ends there. The business is worth about $2.85 billion; after about $1.44 billion of debt, equity is worth about $1.41 billion, or $6.27 per share. Bear case ($0.22 per share). The One Big Beautiful Bill Act, signed July 4, 2025, is projected by the Congressional Budget Office to cut federal Medicaid spending by $1.15 trillion over ten years, with most provisions starting December 31, 2026 or later. The company says the law does not directly change its rates but may limit future rate increases through state budgets. In this case rates freeze while wages keep rising, and cash flow falls back to the 2024 level of about $136 million by year three. That still covers roughly $111 million of interest at today's term-loan rate. The 2032 refinancing costs about one point more, and the Family First purchase repeats the history of write-downs and is worth only half its price. The business is worth about $1.62 billion against about $1.57 billion owed, leaving only about $49 million, or $0.22 per share, for shareholders. Bull case ($9.28 per share). The first-half 2026 operating income pace holds. That pace includes the first-half acquisitions. Business cash flow runs at about $275 million for ten years and then $250 million for 20 more years. Because those acquisitions are counted in the earnings, the cash spent on them is also deducted. The business is worth about $3.63 billion against about $1.54 billion owed, leaving $9.28 per share. What would make this wrong: states cutting or freezing Medicaid rates, a renewed bout of caregiver wage inflation, or SOFR rising, since the term loan floats and the hedges are ending. On the upside, sustained rate increases under the EPSDT mandate could lift results. Shareholders sit behind a large amount of debt, so small changes in cash flow move the per-share value a lot, which is why the margin-of-safety price is well below the base case.